What is Aurinia Pharmaceuticals's market cap?

Aurinia Pharmaceuticals (AUPH) has a market capitalization of $2.0B and trades on NASDAQ.

What is Aurinia Pharmaceuticals's revenue and profitability?

Aurinia Pharmaceuticals generated $298.3M in trailing twelve-month revenue with net income of $298.2M, representing a net margin of 100.0%. Gross margin stands at 89.7%. These figures are based on the Q1 2026 filing.

Who are Aurinia Pharmaceuticals's competitors?

Aurinia Pharmaceuticals's key competitors include Genentech, Inc., Alnylam Pharmaceuticals, Inc., Akebia Therapeutics, Inc., and others. These companies compete in similar markets and product categories.

Who does Aurinia Pharmaceuticals partner with?

Aurinia Pharmaceuticals's notable partners include Otsuka Pharmaceutical Co., Ltd., Lonza Ltd., Catalent Pharma Solutions.

Where is Aurinia Pharmaceuticals headquartered?

Aurinia Pharmaceuticals is headquartered in Canada and employs approximately 300 people. It has been publicly traded since 2009.

Aurinia Pharmaceuticals

AUPH

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for autoimmune diseases with high unmet medical needs.

Market cap

$1.96B+60.1%

Revenue$298.3M+20.6%

Net income$298.2M+648%

EPS (diluted)$2.17+675%

Trailing twelve months · change vs. prior year

Table of contents

Earnings

Q1 2026 report

May 7, 2026

Revenue$77.7MBeat by $726.3K EPS$0.25Beat by $0.07

Read the full report

Next report

Jul 30, 2026 (Tomorrow)

Revenue estimate$80.4M

EPS estimate$0.19

Financials

Q1 2026

Income statement

See full

Revenue$77.7M+24.4%

Gross profit$71.2M+32.1%

Operating income$41.4M+89.6%

Net income$34.4M+47.2%

EPS (diluted)$0.25+56.3%

Balance sheet

See full

Cash & equivalents$41.0M-38.3%

Total debt$85.2M-7.9%

Total equity$567.6M+62.1%

Total assets$724.0M+43.4%

Cash flow

See full

Operating cash flow$32.6M+2,405%

Valuation & ratios

Valuation

See full

Market cap$1.96B+60.1%

Enterprise value$2B+60.6%

P/E6.6×-13.2×

P/S6.6×+1.9×

Profitability

See full

Gross margin89.7%+1.5pp

Operating margin41.7%+29.4pp

Net margin100%+83.9pp

Returns & leverage

See full

Return on equity65%+53.8pp

Debt / equity0.2×-0.1×

Current ratio5.5×-0.4×

Segments

By product

See full

License, collaboration and royalty revenue$4.1M+66.1%

Competitors

By market cap

ALN

Alnylam Pharmaceuticals$37.2B-12.2%

LQD

Liquidia Corporation$7.5B+343%

Rogers Corporation$2.3B+88.4%

Aurinia Pharmaceuticals$2.0B+63.0%

ANI Pharmaceuticals$1.8B+23.7%

Theravance Biopharma$873.8M+58.0%

Puma Biotechnology$406.7M+145%

Akebia Therapeutics$343.4M-63.6%

By revenue growth

LQD

Liquidia Corporation+1,937%

ALN

Alnylam Pharmaceuticals+82.6%

Theravance Biopharma+68.2%

ANI Pharmaceuticals+37.0%

Aurinia Pharmaceuticals+20.6%

Rogers Corporation+4.9%

By net margin

Theravance Biopharma104.34%+194pp

Aurinia Pharmaceuticals99.97%+83.9pp

ALN

Alnylam Pharmaceuticals11.72%+21.5pp

ANI Pharmaceuticals9.98%+13.1pp

Rogers Corporation3.2%+11.3pp

LQD

Liquidia Corporation-176.24%+896pp

Profile

Aurinia Pharmaceuticals is a commercial-stage biopharmaceutical company dedicated to developing and delivering innovative therapies for autoimmune diseases with high unmet medical needs. Its core value proposition is centered on LUPKYNIS, the first FDA-approved oral therapy for adult patients with active lupus nephritis. The company leverages a specialized commercial organization in the U.S. and strategic international partnerships to provide treatments that aim to preserve kidney function and improve long-term patient outcomes.

Competitive position

Aurinia holds a first-mover advantage as the provider of the first FDA-approved oral therapy for lupus nephritis, supported by a robust patent portfolio extending to 2037.

GeographiesUnited States, European Union, Japan, United Kingdom, Switzerland

Customer segmentsSpecialty Pharmacies, Healthcare Providers, Pharmaceutical Companies

Business modelProduct-based, Licensing and Royalties, Research and Development

SuppliersContract manufacturing organizations, Raw material suppliers, Clinical research organizations

CustomersSpecialty pharmacies, Specialty distributors, International licensing partners, Hospitals and clinics

CountryCanada

Listed2009

Employees300.0

CEOKevin C. Tang

SectorHealthcare

IndustryBiotechnology

Websiteauriniapharma.com

FilingsSEC EDGAR

Ask your AI about Aurinia Pharmaceuticals.

Connect your AI assistant and dig into the numbers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Aurinia Pharmaceuticals's market cap?: Aurinia Pharmaceuticals (AUPH) has a market capitalization of $2.0B and trades on NASDAQ.
What is Aurinia Pharmaceuticals's revenue and profitability?: Aurinia Pharmaceuticals generated $298.3M in trailing twelve-month revenue with net income of $298.2M, representing a net margin of 100.0%. Gross margin stands at 89.7%. These figures are based on the Q1 2026 filing.
Who are Aurinia Pharmaceuticals's competitors?: Aurinia Pharmaceuticals's key competitors include Genentech, Inc., Alnylam Pharmaceuticals, Inc., Akebia Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
Who does Aurinia Pharmaceuticals partner with?: Aurinia Pharmaceuticals's notable partners include Otsuka Pharmaceutical Co., Ltd., Lonza Ltd., Catalent Pharma Solutions.
Where is Aurinia Pharmaceuticals headquartered?: Aurinia Pharmaceuticals is headquartered in Canada and employs approximately 300 people. It has been publicly traded since 2009.